Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 274 for “"castration-resistant"”.
-
Personalized treatment of castration resistant prostate cancer
Item does not contain fulltext
-
MECHANISMS OF THERAPEUTIC RESISTANCE IN CASTRATION RESISTANT PROSTATE CANCER
… based chemotherapy is an effective treatment for castration-resistant prostate cancer (CRPC) via stabilization of microtubules. Progression to castration-resistant prostate cancer is characterized by increased androgen receptor (AR), elevated intra-prostatic androgens and activated AR signaling …
-
Effect of simvastatin on castration-resistant prostate cancer cells
In castration-resistant prostate cancer (CRPC), recent evidence has demonstrated the persistence of intratumoral androgens through de novo steroidogenesis despite androgen deprivation therapy. The multi-step androgen synthesis pathway originates from common precursor cholesterol molecule, which can …
-
Saracatinib Synergizes With Enzalutamide In Castration-Resistant Prostate Cancer
… to ADTs and the tumors will transition to castration-resistant prostate cancer (CRPC). Second generation hormonal therapies such as abiraterone acetate and particularly enzalutamide, which inhibits AR full-length (AR-FL), are typically given to men with CRPC. However, these treatments are …
-
Quantitative proteomics and metabolomics of castration resistant prostate cancer
No abstract available.
-
Characterizing glucocorticoid receptor in metastatic castration resistant prostate cancer
… and relevance in the context of enzalutamide resistant prostate cancer cells. Enzalutamide is a drug that functions to dampen androgen receptor (AR) signaling, thus inhibiting cancer dependency on the receptor protein. Although the application of the drug reduces AR signaling in these cancer …
-
OVERCOMING RESISTANCE TO SG-ARIS IN CASTRATION-RESISTANT PROSTATE CANCER
… progresses and develops to a lethal stage called castration-resistant prostate cancer (CRPC) that is characterized by resistance to canonical ADT. To deal with this situation, several second-generation AR inhibitors (SG-ARIs) have been created that have better efficacy against AR, including …
-
Cholesterol metabolism as a target in castration-resistant prostate cancer
… scavenger receptor B1 (SR-B1), is elevated in castration-resistant prostate cancer models and has been linked to poor survival of patients. The overarching hypothesis of this thesis is that cholesterol modulation, through either synthesis or uptake inhibition, will impact essential signaling …
-
Genetic Aberrations And Cholesterol Metabolism In Castration-Resistant Prostate Cancer
… However, an advanced form of the disease, termed castration-resistant PCa (CRPC), accounts for most PCa mortality. PCa is initially dependent on androgens and androgen receptor signaling (AR) for its growth and proliferation. Hence, most therapies for metastatic PCa are directed at inhibiting this …
-
Characterisation and role of SLFN5 in castration resistant prostate cancer
Castration resistant prostate cancer (CRPC) is a currently incurable form of prostate cancer. While varying in different countries, prostate cancer recurrence typically manifests clinically around 12-24 months after androgen deprivation therapy, signifying disease treatment resistance1. Tumour …
-
Identifying Efficacious Therapies for High Glycolysis Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer (mCRPC) remains a deadly disease due to a lack of efficacious treatments. The reprogramming of cancer metabolism toward elevated glycolysis is a hallmark of mCRPC. However, the current drug discovery on finding drugs efficiently inhibiting high …
-
Role of Macrophages in the Development of Castration-Resistant Prostate Cancer
… eventually progress to become therapeutically resistant (castration-resistant prostate cancer, CRPC) and metastasize. The objective of this study was to investigate the role of chronic inflammation in the progression of tumours to become CRPC, and we hypothesized that Timp3 loss and increased …
-
Cellular Delivery of TRAIL to Treat Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer (mCRPC) is currently incurable. When diagnosed at early stages, prostate cancer is very treatable with surgery, radiation, and androgen deprivation (ADT) therapy. Within years, patient tumors will become resistant to ADT and eventually spread becoming …
-
The role of BET proteins in castration-resistant prostate cancer dissemination
… progression of advanced prostate cancer to castration resistance, and ultimately to lethal metastatic disease, depends on primary or acquired resistance to conventional androgen-deprivation therapy (ADT) and accumulated resistance mechanisms to evade androgen receptor (AR) suppression. …
-
Implication of SEMA3C-induced steroidogenesis in the progression of castration-resistant prostate cancer
… prostate tumor cells progress to a treatment-resistant stage known as castration-resistant prostate cancer (CRPC). It has been established that CRPC cells have an acquired ability to synthesize androgens to resist the systemic androgen depletion imposed by ADT. This autonomous steroidogenesis …
-
Understanding the insulin-dependent glucose transporters role in castration-resistant prostate cancer development
El cáncer de próstata es un carcinoma con alta prevalencia que, a diferencia de otros, presenta una correlación inversa con la diabetes tipo I y II. En este sentido, nuestro grupo ha demostrado previamente cómo la inducción de diabetes tipo I en el modelo murino de adenocarcinoma de próstata TRAMP, …
-
GRB10 as a key regulator contributing to the development of castration-resistant prostate cancer
… to androgen ablation, progression to recurrent castration-resistant prostate cancer (CRPC) commonly occur. Current therapies for CRPC, e.g. next-generation ADT including Enzalutamide and Abiraterone, can extend patients’ lives but are not curative as resistance to their use eventually emerges. …
-
Identification of novel androgen receptor inhibitors for the treatment of castration resistant prostate cancer
… capable of combating PCa even in its drug resistant forms. Because the emergence of castration resistance is the lethal end stage of the disease, we anticipate that the thesis work will eventually have a substantial impact on the survival of prostate cancer patients.
-
Development of novel small molecule inhibitor of androgen receptor to treat castration-resistant prostate cancer
… effectiveness, as patients eventually succumb to castration-resistant prostate cancer (CRPC). The clinical onset and progression of most CRPC is accompanied by rising levels of serum prostate specific antigen (PSA), a gene transcriptionally regulated by AR. This indicates aberrant AR …
-
Co-evolution of AR gene copy number and structural complexity in castration-resistant prostate cancer
… will eventually fail during the emergence of castration-resistant prostate cancer (CRPC). CRPC is the lethal from of prostate cancer, and represents a major clinical challenge to managing this disease. The majority of CRPC remains dependent on AR, demonstrating continued reliance on AR …
Page 1 of 14